Filtered By:
Infectious Disease: Epidemics
Management: WHO
This page shows you your search results in order of date.
Order by Relevance | Date
Total 45 results found since Jan 2013.
The U.S. Scientist At the Heart of COVID-19 Lab Leak Conspiracies Is Still Trying to Save the World From the Next Pandemic
Ralph Baric stepped onto the auditorium stage at the University of North Carolina, Chapel Hill, and looked out at the sparse audience that had come to hear him speak. On the large projector screen hanging behind him, the following words appeared: How Bad the Next Pandemic Could Be, What Might It Look Like, and Will We be Ready. The date was May 29, 2018.
“Well, I have to admit I’m a little worried about giving this talk,” Baric said. “The reason is being labelled a harbinger of doom.” The screen shifted, and images of the four horsemen of the apocalypse—Death, Famine, War, and Plague&mda...
Source: TIME: Health - July 11, 2023 Category: Consumer Health News Authors: Dan Werb Tags: Uncategorized COVID-19 feature freelance Source Type: news
Case studies expose deadly risk of mpox to people with untreated HIV
In June 2022, a young man in his 30s severely sick with mpox, the viral disease formerly known as monkeypox, was admitted to the Salvador Zubirán National Institute of Health Sciences and Nutrition hospital in Mexico City. Tests showed the patient was also HIV-positive, which he had not known, and that his blood had few CD4 cells, critical immune cells that HIV attacks. The man’s immune system was so weak it could not keep mpox in check and painful lesions kept spreading across his body, eating away at, or necrotizing, the flesh, according to HIV researcher Brenda Crabtree Ramirez, who was on his care team. Then the vir...
Source: Science of Aging Knowledge Environment - February 21, 2023 Category: Geriatrics Source Type: research
Case studies expose deadly risk of mpox in people with untreated HIV
In June 2022, a young man in his 30s severely sick with mpox, the viral disease formerly known as monkeypox, was admitted to the Salvador Zubirán National Institute of Health Sciences and Nutrition hospital in Mexico City. Tests showed the patient was also HIV-positive, which he had not known, and that his blood had few CD4 cells, critical immune cells that HIV attacks. The man’s immune system was so weak it could not keep mpox in check and painful lesions kept spreading across his body, eating away at, or necrotizing, the flesh, according to HIV researcher Brenda Crabtree Ramirez, who was on his care team. Then the vir...
Source: ScienceNOW - February 21, 2023 Category: Science Source Type: news
Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
LEIDEN, THE NETHERLANDS, (January 18, 2023) – The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, today announced the results of an independent, scheduled data review of the Phase 3 Mosaico study (also known as HPX3002/HVTN706) of Janssen’s investigational HIV vaccine regimen. The study’s independent Data and Safety Monitoring Board (DSMB) determined that the regimen was not effective in preventing HIV infection compared to placebo among study participants. No safety issues with the vaccine regimen were identified.In light of the DSMB’s determination, the Mo...
Source: Johnson and Johnson - January 18, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Scientists race to test vaccines for Uganda ’s Ebola outbreak
A multipronged international effort has begun to pull out all the stops to launch trials of experimental Ebola vaccines in Uganda, which declared an outbreak of the deadly disease on 20 September. According to the most recent World Health Organization (WHO) update, Uganda has had 18 confirmed and 18 suspected cases of Ebola, including 23 deaths—an unusually high case fatality rate of 64%. A trial of a vaccine candidate that’s farthest along in development could launch before the end of next month.
Proven vaccines exist for Zaire ebolavirus, which has led to a dozen outbreaks in the neighboring Democratic Republic ...
Source: ScienceNOW - September 29, 2022 Category: Science Source Type: news
There ’s a shortage of monkeypox vaccine. Could one dose instead of two suffice?
As the monkeypox outbreak grows, the preferred vaccine to combat it is in short supply—a problem that’s only getting worse now that countries are expanding access to the vaccine. But there is a strategy that could double overnight the number of people who can be vaccinated: use a single shot instead of the recommended two.
Compelling data from monkey and human studies suggest a single dose of the vaccine—produced by Bavarian Nordic and sold under three different brand names—solidly protects against monkeypox, and that the second dose mainly serves to extend the durability of protection.
The United Kingdom...
Source: Science of Aging Knowledge Environment - July 1, 2022 Category: Geriatrics Source Type: research
Statement on Data Published in PLOS Medicine on Tolerability and Immune Response of Johnson & Johnson Ebola Vaccine Regimen in Adults Living with HIV
NEW BRUNSWICK, N.J., October 29, 2021 – Data published in PLOS Medicine demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), was well tolerated and induced a robust immune response in both healthy adults and adults living with HIV. These findings, alongside Phase 3 data recently published in The Lancet Infectious Diseases, support the potential prophylactic use of the vaccine regimen to protect people at risk of acquiring Ebola. The regimen was granted Marketing Authorisation by the European Commission in July 2020 and Prequalification from th...
Source: Johnson and Johnson - October 29, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases
NEW BRUNSWICK, N.J., September 13, 2021 – Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), generated robust humoral (antibody) immune responses in adults and children (ages 1-17) with the immune responses persisting in adults for at least two years. The data also showed that booster vaccination with Ad26.ZEBOV, administered to adults two years after the initial vaccination, induced a strong anamnestic (immune) response within seven days. These findings support the potential p...
Source: Johnson and Johnson - September 13, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
Discussions are ongoing with the U.S. Food and Drug Administration regarding the approval of the vaccine regimen in the U.S. WHO Prequalification is often a prerequisite for national registrations of new vaccines and medicines in developing countries. Johnson & Johnson now looks forward to collaborating with the WHO’s African Vaccine Regulatory Forum (AVAREF) to progress national registrations of the Company’s Ebola vaccine regimen. The Company’s Ebola vaccine regimen is designed to be used proactively to induce immunity against Ebola virus disease in adults and children. Johnson & Johnson’s Commitment to E...
Source: Johnson and Johnson - May 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins.
Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news
Johnson & Johnson Announces European Commission Approval for Janssen ’s Preventive Ebola Vaccine
Discussions with the U.S. Food and Drug Administration (FDA) have taken place to define the required data set for filing US licensure. About Janssen’s Ebola Vaccine Regimen The Janssen preventive Ebola vaccine regimen, Ad26.ZEBOV and MVA-BN-Filo, utilizes a non-replicating viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors carry the genetic code of several Ebola virus proteins in order to trigger an immune response.Janssen’s vaccine regimen ori...
Source: Johnson and Johnson - July 1, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Receives Positive CHMP Opinion for Janssen ’s Investigational Preventive Ebola Vaccine Regimen
Discussions with the FDA are ongoing to define the required data set for filing Janssen’s Ebola vaccine regimen under the FDA’s Animal Rule licensure pathway. About Janssen’s Ebola Vaccine Regimen The Janssen investigational preventive Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) utilizes a viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors are modified to safely carry the genetic code of an Ebola virus protein in order to trigger an immun...
Source: Johnson and Johnson - May 29, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia
An epidemic of coronavirus SARS-CoV-2 has become the focus of scientific attention.1 The high infectivity of SARS-CoV-2 and rapid rise in the number of patients affected reflects the lack of preexisting immunity as reported by the World Health Organization (https://www.who.int/emergencies/diseases/novel-coronavirus-2019). The clinical presentation of coronavirus disease 2019 (COVID-19) is variable, ranging from lack of symptoms to severe respiratory distress and multiorgan failure req uiring intensive care unit admission and mechanical ventilation.
Source: Journal of Allergy and Clinical Immunology - April 21, 2020 Category: Allergy & Immunology Authors: Isabella Quinti, Vassilios Lougaris, Cinzia Milito, Francesco Cinetto, Antonio Pecoraro, Ivano Mezzaroma, Claudio Maria Mastroianni, Ombretta Turriziani, Maria Pia Bondioni, Matteo Filippini, Annarosa Soresina, Giuseppe Spadaro, Carlo Agostini, Rita Carse Tags: Letter to the Editor Source Type: research
China ’s Draconian Lockdown Is Getting Credit for Slowing Coronavirus. Would It Work Anywhere Else?
As COVID-19 spread rapidly across China, authorities took an aggressive stance to fight the coronavirus. They were slow to respond to the outbreak—at first suppressing information and denying that it could spread between humans even as it did just that. But, as case numbers skyrocketed, Beijing went to extraordinary lengths to fight the virus, identified at COVID-19, in a campaign Chinese President Xi Jinping has described as a “people’s war.”
The most dramatic, and controversial, of the measures was the lockdown of of tens of millions of people in what is believed to be the largest quasi-quarantin...
Source: TIME: Health - March 13, 2020 Category: Consumer Health News Authors: Amy Gunia Tags: Uncategorized COVID-19 overnight Source Type: news
Why Wearing a Face Mask Is Encouraged in Asia, but Shunned in the U.S.
Cheryl Man is usually the only one wearing a face mask on her New York City subway train. She notices this, but other people on the train notice, too. Usually she just gets odd stares from other commuters. But on Tuesday morning, when she was walking to school, a group of teens jeered at her and coughed in her direction.
“I felt very humiliated and misunderstood,” says Man, a 20-year-old student and research assistant who is ethnically Chinese.
Man also feels the stigma at her workplace, where she keeps her mask on. None of her colleagues wear a face mask, and some of them have asked her if she is sick.
̶...
Source: TIME: Health - March 12, 2020 Category: Consumer Health News Authors: Hillary Leung / Hong Kong Tags: Uncategorized COVID-19 onetime overnight Source Type: news
